Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR57667B in Early Parkinson's Disease
NCT00228150Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2003
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of xaliproden in Parkinson's disease (PD), sponsored by Sanofi. Started Jul 2003; status: completed.
02
Drugs
xaliproden
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00228150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00228150.